Adefovir dipivoxilAdefovir
Find information on thousands of medical conditions and prescription drugs.

Hepsera

Adefovir dipivoxil, previously called bis-POM PMEA, with trade names Preveon® and Hepsera®, is an orally-administered nucleotide analog reverse transcriptase inhibitor (NRTI) used for treatment of Hepatitis B. It is a failed treatment for HIV. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
Habitrol
Halcion
Haldol
Haloperidol
Halothane
Heparin sodium
Hepsera
Herceptin
Heroin
Hetacillin
Hexachlorophene
Hexal Diclac
Hexal Ranitic
Hexetidine
Hibiclens
Histidine
Hivid
HMS
Hyalgan
Hyaluronidase
Hycodan
Hycomine
Hydralazine
Hydrochlorothiazide
Hydrocodone
Hydrocortisone
Hydromorphone
Hydromox
Hydroxycarbamide
Hydroxychloroquine
Hydroxystilbamidine
Hydroxyzine
Hyoscine
Hypaque
Hytrin
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

History

Adefovir was originally developed by Gilead Sciences for HIV with the brand name Preveon. However, in November 1999, an expert panel advised the U.S. Food and Drug Administration (FDA) not to approve the drug due to concerns about the severity and frequency of kidney toxicity when dosed at 60 or 120mg. The FDA followed that advice, refusing to approve adefovir as a treatment for HIV.

Gilead Sciences discontinued its development for HIV treatment in December 1999 but continued to develop the drug for Hepatitis B (HBV), where it is effective with a much lower dose. FDA approval for use in the treatment of Hepatitis B was granted on September 20, 2002, and adefovir is sold for this indication under the brand name Hepsera.

Adefovir became an approved treatment for HBV in the United States in September 2002 and in the European Union in March 2003. The main benefit of Adefovir over Lamivudine (the first NRTI approved for the treatment of Hepatitis B) is that it takes a much longer period of time before the virus develops resistance to it.

Mechanism of action

Adefovir works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.

It is approved for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (primarily ALT) or histologically active disease.

Adefovir is a failed treatment for HIV due to the severity and frequency of kidney toxicity when dosed at 60 or 120mg. However, trials have found the 10mg dose of adefovir to be an effective and safe treatment for HBV. The main benefit of Adefovir over lamivudine is that it takes a much longer period of time before the virus develops resistance to it.

Read more at Wikipedia.org


[List your site here Free!]


Hepsera. (New & Approved). : An article from: Internal Medicine News $5.95 Hepsera. (New & Approved). : An article from: Family Practice News $5.95
Hepsera reduces lamivudine-resistant HBV levels in liver transplant patients.(hepatitis B) : An article from: Transplant News $5.95

Adefovir for chronic hepatitis B infection - Hepsera - STEPS
Safety: Adefovir is associated with several toxicities that warrant careful patient monitoring. (1,2) Due to treatment-limiting nephrotoxicity, all patients receiving adefovir need routine monitori
FDA approvals. for the treatment of hypertension; adefovir dipivoxil for the treatment of hepatitis B - eplerenone Inspra - Hepsera
Eplerenone. The U.S. Food and Drug Administration (FDA) has approved eplerenone (Inspra) for the treatment of high blood pressure. Eplerenone works ...
European Cpmp Gives Positive Recommendation For Hepsera
Gilead Sciences, Inc. (Nasdaq:GILD), Foster City, Calif. has announced that the European Union's Committee for Proprietary Medicinal Products (CPMP), ...
Five-Year Data Evaluating Long-Term Therapy with Hepsera® for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Presented at AASLD Annual Meeting
SAN FRANCISCO -- Data Indicate that Hepsera May Lead to Regression of Liver Fibrosis in Patients Treated for up to Five Years Gilead Sciences (Nasdaq:GILD) ...
Valeant Pharmaceuticals Presents Positive Interim Data on Pradefovir Mesylate at AASLD; 24-Week Interim Results Show Pradefovir Statistically Better Than
SAN FRANCISCO -- Valeant Pharmaceuticals International (NYSE:VRX) yesterday afternoon presented interim results from a Phase 2 study of its oral anti-viral ...
Entecavir approved for chronic hepatitis B
GAITHERSBURG, MD. -- Entecavir, an oral antiviral drug that has several advantages over currently available treatments for chronic hepatitis B, was approved recently by the Food and Drug Administra
Data Evaluating Long-Term Therapy with Hepsera for Hepatitis B ''e'' Antigen-Negative Chronic Hepatitis B Published in the New England Journal of Medicine
FOSTER CITY, Calif. -- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that data through 144 weeks supporting the efficacy and tolerability of its ...
Gilead Announces Long-Term Safety and Efficacy Data, Through 144 Weeks, for Hepsera in Patients With Chronic Hepatitis B
BOSTON -- Data Show Increasing Serologic, Virologic and Biochemical Response Over 144 Weeks in Treatment-Naive Hepatitis B "e" Antigen-Positive ...

Home Contact Resources Exchange Links ebay